Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.6781
+0.0150 (2.26%)
At close: Dec 30, 2025, 4:00 PM EST
0.6752
-0.0029 (-0.43%)
After-hours: Dec 30, 2025, 4:44 PM EST
Vistagen Therapeutics Revenue
Vistagen Therapeutics had revenue of $258.00K in the quarter ending September 30, 2025, with 40.98% growth. This brings the company's revenue in the last twelve months to $721.00K, down -17.60% year-over-year. In the fiscal year ending March 31, 2025, Vistagen Therapeutics had annual revenue of $486.00K, down -54.32%.
Revenue (ttm)
$721.00K
Revenue Growth
-17.60%
P/S Ratio
29.88
Revenue / Employee
$12,649
Employees
57
Market Cap
26.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 486.00K | -578.00K | -54.32% |
| Mar 31, 2024 | 1.06M | 1.29M | - |
| Mar 31, 2023 | -227.00K | -1.34M | - |
| Mar 31, 2022 | 1.11M | 19.40K | 1.78% |
| Mar 31, 2021 | 1.09M | - | - |
| Mar 31, 2020 | - | - | - |
| Mar 31, 2019 | - | - | - |
| Mar 31, 2018 | - | - | - |
| Mar 31, 2017 | 1.25M | - | - |
| Mar 31, 2016 | - | - | - |
| Mar 31, 2015 | - | - | - |
| Mar 31, 2014 | - | - | - |
| Mar 31, 2013 | 200.40K | -1.14M | -85.07% |
| Mar 31, 2012 | 1.34M | -728.80K | -35.19% |
| Mar 31, 2011 | 2.07M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VTGN News
- 13 days ago - Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study - Benzinga
- 13 days ago - Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Business Wire
- 4 weeks ago - Vistagen Appoints Nick Tressler as Chief Financial Officer - Business Wire
- 4 weeks ago - Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting - Business Wire
- 6 weeks ago - Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 - Seeking Alpha
- 6 weeks ago - Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update - Business Wire
- 7 weeks ago - Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025 - Business Wire